Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGY-1601-VT
- Development stage
- Phase 2
- Lead developer
- Nexbiome Therapeutics
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
BGY-1601-VT is a live biotherapeutic product developed by Nexbiome Therapeutics. It is being investigated as a first-line monotherapy for women with acute vaginal infections, including bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and mixed infections. The drug is formulated as a vaginal tablet and aims to treat acute vaginal infection without requiring an upfront microbiological diagnosis. Its mechanism of action has not been disclosed or remains unknown in public sources. The highest reported phase of development for this indication is Phase 2[1][3][4][5][7].
- Other names
- Lcr35Lcr-35Lcr 35Lacticaseibacillus rhamnosus Lcr35
Beyond the preview
Go deeper on BGY-1601-VT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGY-1601-VT.